Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include: Biliary cirrhosis.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 1 | Biliary cirrhosis |
Biomarker and diagnostic research for primary biliary cholangitis 1 has been reported in the published literature.
No clinical trials have been registered for primary biliary cholangitis 1.
251 publications have been identified in PubMed for primary biliary cholangitis 1. Kisho has analyzed 190 by research type. Research spans Review / Meta-Analysis (32%), Basic Science / Preclinical (19%), and Epidemiology / Natural History (19%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 61 | 32% |
Data assembled from 4 of 12 sources · Last updated Nov 3, 2026, 2:28 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Laboratory research |
36 |
19% |
Disease patterns and progression | 36 | 19% |
Clinical study results | 27 | 14% |
Testing and diagnosis research | 19 | 10% |
Other research | 4 | 2% |
New treatment approaches | 4 | 2% |
Patient case studies | 3 | 2% |
Gish RG (2026). [PMID: 41693640](https://pubmed.ncbi.nlm.nih.gov/41693640/). *J Comp Eff Res*. [Epidemiology / Natural History]
Hirschfield GM (2026). [PMID: 41173016](https://pubmed.ncbi.nlm.nih.gov/41173016/). *Lancet Gastroenterol Hepatol*. [Clinical Trial Publication]
Xi J (2026). [PMID: 41678453](https://pubmed.ncbi.nlm.nih.gov/41678453/). *PLoS One*. [Gene Therapy / Novel Therapeutics]
Garcia-Torralba A (2026). [PMID: 41572859](https://pubmed.ncbi.nlm.nih.gov/41572859/). *Scand J Rheumatol*. [Epidemiology / Natural History]
Yuan L (2026). [PMID: 41407857](https://pubmed.ncbi.nlm.nih.gov/41407857/). *Nature*. [Basic Science / Preclinical]
Nikolaidis M (2026). [PMID: 41975274](https://pubmed.ncbi.nlm.nih.gov/41975274/). *Gut Microbes*. [Basic Science / Preclinical]
Jin Y (2026). [PMID: 41406704](https://pubmed.ncbi.nlm.nih.gov/41406704/). *Hum Immunol*. [Basic Science / Preclinical]
Martins A (2026). [PMID: 41869905](https://pubmed.ncbi.nlm.nih.gov/41869905/). *Aliment Pharmacol Ther*. [Review / Meta-Analysis]
Xu J (2026). [PMID: 41539656](https://pubmed.ncbi.nlm.nih.gov/41539656/). *J Gastroenterol Hepatol*. [Epidemiology / Natural History]
Andrzejuk A (2026). [PMID: 42221308](https://pubmed.ncbi.nlm.nih.gov/42221308/). *Clin Exp Hepatol*. [Review / Meta-Analysis]
AI-curated news mentioning primary biliary cholangitis 1
Updated Oct 6, 2026
Interim analysis from the ASSURE trial shows that seladelpar significantly improves liver stiffness in patients with primary biliary cholangitis (PBC). This finding supports the potential of seladelpar as a therapeutic option for this rare liver disease.
Recent research indicates that statins may reduce the risk of disease progression and mortality in non-cirrhotic patients with primary biliary cholangitis. This finding could influence treatment strategies for managing this rare liver disease.
A systematic review and meta-analysis evaluated the safety profile of elafibranor in patients with primary biliary cholangitis compared to placebo. The findings contribute to understanding the drug's safety in this rare liver disease.
The Scottish Medicines Consortium has accepted Livdelzi for the treatment of primary biliary cholangitis, enhancing treatment options for patients suffering from chronic itch associated with the disease. This decision marks a significant step in addressing the unmet needs of this patient population.
The CHMP has recommended Lynavoy for EU approval as the first IBAT inhibitor targeting cholestatic pruritus in primary biliary cholangitis (PBC). This marks a significant advancement in treatment options for patients suffering from this rare condition.